High-dose Dual Therapy With Different Administration Frequencies
Status:
Recruiting
Trial end date:
2023-09-25
Target enrollment:
Participant gender:
Summary
This study is a single center, randomized controlled clinical study. The enrolled patients
are HP positive. They are diagnosed as HP positive by rapid urease test and/or 13C urea
breath test. According to the declaration of Helsinki, 274 patients will be included in this
study. After obtaining the written informed consent of the patients, HP culture and drug
sensitivity test will be conducted on all the selected patients with the success rate,
adverse reactions, compliance, antibiotic resistance of HP and its impact on HP eradication.